학술논문
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Document Type
Article
Author
Source
In Blood 15 November 2008 112(10):3959-3964
Subject
Language
ISSN
0006-4971